CA3240577A1 - Methods of treating hypertension by periodic suppression of aldosterone synthase - Google Patents
Methods of treating hypertension by periodic suppression of aldosterone synthase Download PDFInfo
- Publication number
- CA3240577A1 CA3240577A1 CA3240577A CA3240577A CA3240577A1 CA 3240577 A1 CA3240577 A1 CA 3240577A1 CA 3240577 A CA3240577 A CA 3240577A CA 3240577 A CA3240577 A CA 3240577A CA 3240577 A1 CA3240577 A1 CA 3240577A1
- Authority
- CA
- Canada
- Prior art keywords
- subject
- cyp
- beta hydroxylase
- hydroxylase inhibitor
- serum
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263300967P | 2022-01-19 | 2022-01-19 | |
| US63/300,967 | 2022-01-19 | ||
| US202263400301P | 2022-08-23 | 2022-08-23 | |
| US63/400,301 | 2022-08-23 | ||
| PCT/IB2023/050444 WO2023139506A1 (en) | 2022-01-19 | 2023-01-19 | Methods of treating hypertension by periodic suppression of aldosterone synthase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3240577A1 true CA3240577A1 (en) | 2023-07-27 |
Family
ID=87347916
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3240577A Pending CA3240577A1 (en) | 2022-01-19 | 2023-01-19 | Methods of treating hypertension by periodic suppression of aldosterone synthase |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20250099475A1 (https=) |
| EP (1) | EP4466021A4 (https=) |
| JP (1) | JP2025503015A (https=) |
| KR (1) | KR20240140102A (https=) |
| CA (1) | CA3240577A1 (https=) |
| TW (1) | TW202339758A (https=) |
| WO (1) | WO2023139506A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2025527706A (ja) * | 2022-08-23 | 2025-08-22 | ミネラリス・セラピューティクス・インコーポレイテッド | 肥満対象における高血圧を治療する方法 |
| CA3265668A1 (en) * | 2022-08-23 | 2024-02-29 | Mineralys Therapeutics, Inc. | METHODS OF TREATING HYPERTENSION WITH A COMBINATION OF AN ALDOSTERONE SYNTHASE INHIBITOR AND A DIURETIC |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2886117C (en) * | 2012-10-05 | 2022-05-31 | Merck Sharp & Dohme Corp. | Indoline compounds and their use as aldosterone synthase inhibitors |
| JP6067181B2 (ja) * | 2013-04-30 | 2017-01-25 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | アルドステロンシンターゼ阻害薬 |
| MY176401A (en) * | 2014-04-24 | 2020-08-05 | Mitsubishi Tanabe Pharma Corp | Novel disubstituted 1,2,4-triazine compound |
| JP2023546970A (ja) * | 2020-10-26 | 2023-11-08 | ミネラリス・セラピューティクス・インコーポレイテッド | 高血圧のためのｃｙｐ１１ｂ２ベータヒドロキシラーゼ阻害剤 |
-
2023
- 2023-01-19 TW TW112102537A patent/TW202339758A/zh unknown
- 2023-01-19 EP EP23743048.3A patent/EP4466021A4/en active Pending
- 2023-01-19 WO PCT/IB2023/050444 patent/WO2023139506A1/en not_active Ceased
- 2023-01-19 JP JP2024543009A patent/JP2025503015A/ja active Pending
- 2023-01-19 CA CA3240577A patent/CA3240577A1/en active Pending
- 2023-01-19 US US18/730,540 patent/US20250099475A1/en active Pending
- 2023-01-19 KR KR1020247027543A patent/KR20240140102A/ko active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4466021A4 (en) | 2026-01-14 |
| US20250099475A1 (en) | 2025-03-27 |
| WO2023139506A1 (en) | 2023-07-27 |
| JP2025503015A (ja) | 2025-01-30 |
| EP4466021A1 (en) | 2024-11-27 |
| TW202339758A (zh) | 2023-10-16 |
| KR20240140102A (ko) | 2024-09-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Weir et al. | Treatment with patiromer decreases aldosterone in patients with chronic kidney disease and hyperkalemia on renin-angiotensin system inhibitors | |
| Khder et al. | Sacubitril/valsartan (LCZ696) in heart failure | |
| Luther et al. | Aldosterone deficiency and mineralocorticoid receptor antagonism prevent angiotensin II–induced cardiac, renal, and vascular injury | |
| JP2002529405A (ja) | 心臓血管系疾患による発病率及び死亡率減少のためのアンギオテンシン変換酵素阻害薬及びアルドステロン拮抗薬の併用療法 | |
| US9387249B2 (en) | Methods of treating hypertension with at least one angiotensin II receptor blocker and chlorthalidone | |
| JP7814368B2 (ja) | 慢性腎疾患の治療のためのジボテンタン及びダパグリフロジンの組み合わせ | |
| Amar et al. | Sequential comparison of aldosterone synthase inhibition and mineralocorticoid blockade in patients with primary aldosteronism | |
| US20250099475A1 (en) | Methods of treating hypertension by periodic suppression of aldosterone synthase | |
| Tylicki et al. | The enhanced renin-angiotensin-aldosteron system pharmacological blockade-which is the best? | |
| Ubaid‐Girioli et al. | Aldosterone escape with diuretic or angiotensin‐converting enzyme inhibitor/angiotensin II receptor blocker combination therapy in patients with mild to moderate hypertension | |
| Theodor et al. | Absolute bioavailability of moxonidine | |
| CN110785168A (zh) | 用于预防或治疗猫的全身性疾病的血管收缩素ii受体拮抗剂 | |
| US20260053811A1 (en) | Methods of treating hypertension in obese subjects | |
| US20260053812A1 (en) | Methods of treating hypertension with a combination of an aldosterone synthase inhibitor and a diuretic | |
| Marino et al. | Pharmacodynamics and pharmacokinetics of irbesartan in patients with mild to moderate hypertension | |
| Elliott et al. | Pharmacology of antihypertensive drugs | |
| WO2025024488A2 (en) | Methods of treating hypertension with a combination of lorundrostat and two or more anti-hypertensive medications | |
| EP1842543A1 (en) | Pharmaceutical composition coprising an aldosterone synthase inhibitor and a mineralcorticoid receptor antagonist | |
| TW202510887A (zh) | 以勞倫卓司他(lorundrostat)或勞倫卓司他與sglt2抑制劑之組合治療慢性腎臟病(ckd)或ckd與高血壓之方法 | |
| EA044411B1 (ru) | Антагонист рецептора ангиотензина ii для предотвращения или лечения системных заболеваний у котов |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250117 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250117 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250117 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260112 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260112 |